|
|
|
| Clinical effect of Octreotide in the treatment of 120 patients with liver cirrhosis and upper gastrointestinal bleeding |
| DING Bai-ling |
| Department of Gastroenterology,the Second Affiliated Hospital of Shenyang Medical College,Liaoning Province,Shenyang 110002,China |
|
|
|
|
Abstract Objective To investigate the clinical effect of Octreotide in the treatment of patients with liver cirrhosis and upper gastrointestinal bleeding.Methods A total of 120 patients with liver cirrhosis and upper gastrointestinal hemorrhage admitted to the Second Affiliated Hospital of Shenyang Medical College from January 2017 to January 2020 were selected as the research subjects.These patients were divided into an observation group and a control group by random number table method,with 60 cases in each group.Patients in the control group were treated with Pituitrin,and in the observation group,they were treated with Octreotide.The clinical effect,the hemostasis rate of 1,2,3 days after treatment,hemostasis time,3 months follow-up rebleeding rate,hospital stay,blood transfusion volume and total incidence of adverse reactions were compared between the two groups.Results The total effective rate of observation group was higher than that of control group,and the difference was statistically significant (P＜0.05).The hemostatic rate of the observation group was higher than that of the control group at 1 day after treatment,and the difference was statistically significant(P＜0.05).There were no significant differences in the hemostatic rates at 2 and 3 days after treatment between the two groups (P＜0.05).The hemostatic rate of the observation group at 2 days after treatment was not significantly different from that of 1 day after treatment(P＞0.05).The hemostatic rate of the observation group at 3 days after treatment was lower than that of 1 day after treatment,and the difference was statistically significant (P＜0.05).The hemostatic rates of the control group at the 2 and 3 days after treatment were not significantly different from those of the 1 day after treatment (P＞0.05).The hemostasis time and hospitalization time in the observation group were shorter than those in the control group,and the blood transfusion amount was less than that in the control group,and the differences were statistically significant (P＜0.05).There was no significant difference in the rebleeding rate within 3 months follow-up rebleeding rate between the two groups compared with the total incidence of adverse reactions (P＞0.05).Conclusion The application of Octreotide in the treatment of liver cirrhosis complicated with upper gastrointestinal bleeding can improve the effect,promote fast hemostasis,shorten hemostasis time and hospital stay and reduce blood transfusion.
|
|
|
|
|
|
| [8] |
魏建明.奥曲肽联合普萘洛尔治疗肝硬化并发上消化道出血的疗效观察[J].临床研究，2019，27（1）：59-61.
|
| [9] |
王春玲.奥曲肽治疗肝硬化并发上消化道出血的临床分析[J].中国冶金工业医学杂志，2018，35（6）：693.
|
| [10] |
武清华.分析联合应用奥曲肽与普萘洛尔治疗肝硬化并发上消化道出血的临床疗效[J].世界最新医学信息文摘（连续型电子期刊），2019，19（48）：134，138.
|
| [11] |
王明，倪志.奥曲肽治疗后177例肝硬化并发上消化道出血患者临床疗效研究[J].实用肝脏病杂志，2018，21（1）：114-115.
|
| [1] |
金秋菊.奥曲肽治疗乙型肝炎肝硬化并发上消化道出血的临床疗效[J].中国医药指南，2020，18（6）：24-25.
|
| [2] |
崔本红.垂体后叶素联合奥曲肽对肝硬化上消化道出血患者Hb 水平及并发症的影响[J].淮海医药，2019，37（6）：646-648.
|
| [3] |
王永杰.观察奥曲肽治疗肝硬化并发症上消化道出血患者的临床应用价值[J].饮食保健，2019，6（38）：60.
|
| [4] |
张吉峰.奥曲肽治疗肝硬化并发上消化道出血的临床分析[J].中外医疗，2019，38（22）：100-102.
|
| [5] |
王正秀.联用奥曲肽和奥美拉唑治疗肝硬化并发上消化道出血的效果观察[J].当代医药论丛，2019，17（13）：148-149.
|
| [6] |
琼吉.奥曲肽治疗肝硬化并发上消化道出血的临床效果研究[J].饮食保健，2019，6（9）：81.
|
| [7] |
王傲然，张欣鑫.奥曲肽治疗后120例肝硬化并发上消化道出血患者临床疗效研究[J].养生保健指南，2019，17（8）：63.
|
| [12] |
廖怀利.奥曲肽对肝硬化患者并发上消化道出血的止血疗效评价[J].抗感染药学，2018，15（9）：1592-1594.
|
| [13] |
付远.醋酸奥曲肽联合盐酸普萘洛尔治疗肝硬化门静脉高压性上消化道出血观察[J].健康大视野，2019，21（11）：42.
|
| [14] |
张驰松.奥曲肽治疗乙肝肝硬化并发上消化道出血的临床疗效分析[J].北方药学，2016，13（9）：41.
|
| [15] |
吉茜茜，郑志存.奥曲肽联合兰索拉唑治疗门脉高压性上消化道出血的临床效果[J].肝脏，2019，24（5）：594-595.
|
|
|
|
